CoChat

TC‐5214 (S‐(+)‐Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity

Open access
Lippiello, Patrick M., Beaver, Jessica S., Gatto, Gregory J., James, John W., Jordan, Kristen G., Traina, Vincent M., Xie, Jianxun, Bencherif, Merouane · 2008 · CNS Neuroscience & Therapeutics
Cited by 82

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Both clinical and preclinical data support a potential therapeutic benefit of modulating the activity of CNS neuronal nicotinic receptors (NNRs) to treat depression and anxiety disorders. Based on the notion that the depressive states involve hypercholinergic tone, we have examined the potential palliative role of NNR antagonism in these disorders, using TC‐5214 (S‐(+) enantiomer of mecamylamine), a noncompetitive NNR antagonist. TC‐5214 demonstrated positive effects in a number of animal models of depression and anxiety. TC‐5214 was active in the forced swim test in rats (minimum effective dose (MED) = 3 mg/kg i.p.), a classical depression model. It was also active in the behavioral despair test in mice (0.1–3.0 mg/kg i.p.), another model of depression. In the social interaction paradigm in rats, a model of generalized anxiety disorder (GAD), TC‐5214 was active at a dose of 0.05 mg/kg s.c. In the light/dark chamber paradigm in rats, a model of GAD and phobia, TC‐5214 was also active at a dose of 0.05 mg/kg s.c. Although TC‐5214 shows modest selectivity among NNR subtypes, the antidepressant and anxiolytic effects seen in these studies are likely attributable to antagonist effects at the α4β2 NNRs. This is supported by the observation of similar effects with α4β2‐selective partial agonists such as cytisine and with α4β2‐selective antagonists such as TC‐2216. TC‐5214 was well tolerated in acute and chronic toxicity studies in mice, rats, and dogs, showed no mutagenicity and displayed safety pharmacology, pharmacokinetic and metabolic profiles appropriate for therapeutic development. Overall, the results support a novel nicotinic cholinergic antagonist mechanism for antidepressant and anxiolytic effects and highlight the potential of NNR antagonists such as TC‐5214 as therapeutics for the treatment of anxiety and depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-5949.2008.00054.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 82

Metadata

Authors
Lippiello, P. M., Beaver, J. S., Gatto, G. J., James, J. W., Jordan, K. G., Traina, V. M., Xie, J., & Bencherif, M.
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2008-11-11
Volume
14
Issue
4
Pages
266-277
ISSN
  • 1755-5930 (ISSN-L)
  • 1755-5949
OpenAlex
W2066658868
Cited by
82
References
16
FWCI
3.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TC‐5214 (S‐(+)‐Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity. https://app.cochat.ai/papers/10.1111/j.1755-5949.2008.00054.x
The paper
Lippiello, P. M., Beaver, J. S., Gatto, G. J., James, J. W., Jordan, K. G., Traina, V. M., Xie, J., & Bencherif, M. (2008). TC‐5214 (S‐(+)‐Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2008.00054.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.